Breast Cancer Foundation NZ
Observation Toxicity Study
Early Breast Cancer clinical trials for ER+
Recruiting
Updated: January 20, 2022
This is an observational cohort study of toxicity in female patients treated for early breast cancer with Adriamycin and Cyclophosphamide chemotherapy.
This is an observational cohort study of toxicity in female patients treated for early breast cancer with Adriamycin and Cyclophosphamide chemotherapy.
Key inclusion criteria
- Age = 18 years.
- Female patients receiving Adriamycin (60mg/m2) and Cyclophosphamide (600mg/m2) chemotherapy for early breast cancer in the study institution(s).
- Adequate pre-treatment bone marrow function defined as absolute neutrophil count = 1.5×106/L , platelet count = 100×109/L.
- Calculated creatinine clearance by Cockroft-Gault or MDRD (Modification of Diet in Renal Disease) equation of = 60ml/min.
- Ability to understand and the willingness to sign a written informed consent document.
Key exclusion criteria
- Previous exposure to cytotoxic agents or long-term immunosuppression.
- Patient not willing to have chemotherapy at the study centre(s).
- Known hypersensitivity to Adriamycin or Cyclophosphamide.
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
New Zealand
If you think you might be a candidate for this trial, use the contact details supplied, or talk to your doctor.
Want to access a trial that's not in your area? It's not always possible, but if you're interested, email us at intouch@bcf.org.nz
Similar clinical trials
For Early Breast Cancer
Are we out of date? If you have updated or new information about a trial, we’d be grateful if you’d share it with us – email your update to intouch@bcf.org.nz
Interested in a clinical trial?
Subscribe for updates & stay in the loop with new studies.